Wayne State University
Medical Student Research Symposium

School of Medicine

March 2020

Renal Safety and Racial Disparity in Patients on Antiviral
Treatment for Chronic Hepatitis B
Matthew Miller
mamiller@med.wayne.edu

Sindhuri Benjaram
Raya Kutaimy
Paul Naylor
Wayne State University, phnaylor@gmail.com

Elizabeth May

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wayne.edu/som_srs
Part of the Chemical and Pharmacologic Phenomena Commons, Demography, Population, and
Ecology Commons, Inequality and Stratification Commons, Medical Pharmacology Commons, Medical
Toxicology Commons, and the Race and Ethnicity Commons

Recommended Citation
Miller, Matthew; Benjaram, Sindhuri; Kutaimy, Raya; Naylor, Paul; May, Elizabeth; Ehrinpreis, Murray; and
Mutchnick, Milton, "Renal Safety and Racial Disparity in Patients on Antiviral Treatment for Chronic
Hepatitis B" (2020). Medical Student Research Symposium. 40.
https://digitalcommons.wayne.edu/som_srs/40

This Research Abstract is brought to you for free and open access by the School of Medicine at
DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an
authorized administrator of DigitalCommons@WayneState.

Authors
Matthew Miller, Sindhuri Benjaram, Raya Kutaimy, Paul Naylor, Elizabeth May, Murray Ehrinpreis, and
Milton Mutchnick

This research abstract is available at DigitalCommons@WayneState: https://digitalcommons.wayne.edu/som_srs/40

Renal Safety and Racial Disparity in Patients on Anti-viral Treatment for Chronic
Hepatitis B
Matthew J. Miller, Sindhuri Benjaram, Raya Kutaimy, Paul Naylor, Elizabeth May, Murray
Ehrinpreis, Milton Mutchnick
Division of Gastroenterology, Wayne State University School of Medicine
Background:
Many African Americans (AA) are chronically infected with Hepatitis B (HBV). While antiviral
therapy is highly effective, clinical trials suggest a treatment-related decline in kidney function is
possible. Given that chronic HBV predominately affects Asians worldwide, most studies have
contained few AA patients. We evaluated these treatment-related kidney function changes in our
predominately AA patient population.
Methods:
From 225 HBV patients, we identified 42 patients who were not co-infected with HIV or HCV, had
a recent visit, and at least one earlier visit (before Jan 2017). If on treatment with antivirals it must
have been for at least 2 years. There were 27 AA (65%) and 15 non-AA (7 Asian, 6 Caucasian,
2 other). There were 24 patients on antiviral treatment and 18 patients not on treatment. Most
patients were treated with tenofovir disoproxil fumarate (TDF; n= 19), with the remaining 5 treated
with entecavir. Serum creatinine levels (mg/dL) and glomerular filtration rate (GFR;
mL/min/1.73m2) were obtained from the earliest visit and the most recent visit. The average time
between measurements was 7.4 years (range from 2-15; median 6.5).
Results :
The data in the figure below presents the average creatinine and GFR for all patients by race both
before and after treatment. The p-value is for pairwise analysis of the change between the two
visits. Patients treated with antivirals had nearly double the increase in serum creatinine as
compared to untreated patients (treated: 0.091± 0.0439, p<0.05; vs untreated: 0.047 ± 0.045, not
significant). There was also a greater decrease in kidney function as defined by GFR for patients
on treatment as compared to untreated patients (treated: -13.9 ± 5.0, p<0.05; vs untreated: -11.3
± 5.9, not significant). The creatinine increase was also significant in AA but not in non-AA (+0.76
for AA, p<0.05; vs +0.11 for non-AA). Racial disparity for GFR was not as noticeable (-12.2/95.2=
13% decrease; p<0.005 for AA, and -16.2/92.3= 18% decrease; p<0.05 for non-AA). When limited
to just TDF, the induced increase in creatinine (+0.10; p<0.05) and the decline in GFR (-14;
p<0.005) were statistically significant.
Conclusions:
While few patients had a clinically relevant rise in creatinine and/or decrease in GFR to raise the
issue of stopping medication, the value of continuing to monitor especially the AA patients on antiviral treatment is revealed by our data. The data supports the counselling of AA patients that
switching to the newer formulation of tenofovir alafenamide (TAF) which is associated with less
renal toxicity than TDF should be strongly considered.
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The decline in kidney function (increase in serum creatinine (mg/dL) and decrease in glomerular
filtration rate (GFR; mL/min/1.73m2)) is presented for race and treatment. The statistical significance
was determined using pairwise analysis. The number of patients is in parentheses for each group.
The error bars are the standard error of the mean. Pre is earliest measurement and post is a
measurement at least two years after first measurement.

